Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. IBM

Go back to Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients

Supernus Pharma (SUPN) Misses Q3 EPS by 6c, Revenues Miss; Lowers FY19 Sales Views, Reports Topline Data from Ph. 3 Study of SPN-810

November 5, 2019 4:57 PM EST

Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.54, $0.06 worse than the analyst estimate of $0.60. Revenue for the quarter came in at $102.1 million versus the consensus estimate of $109.44 million.

Total revenue of $102.1 million, compared to $103.0 million in third quarter 2018Net product sales of $100.0 million, compared to $100.2 million in third quarter 2018Operating earnings of $39.7 million, compared to $37.5 million in third quarter 2018NDA... More